# Risankizumab-Rzaa (Skyrizi)

Source: https://ourhealthnetwork.com/drugs/risankizumab-rzaa
Data: FDA Orange Book and OpenFDA, refreshed periodically

## What is Risankizumab-Rzaa?

Risankizumab-Rzaa (brand name: Skyrizi) is an interleukin-23 antagonist. It is prescribed to treat psoriasis. Across the United States, 2,000 doctors prescribe Risankizumab-Rzaa to approximately 1,000 Medicare patients.

## Brand names

Skyrizi

## Indications

Risankizumab-Rzaa is primarily prescribed for the treatment of psoriasis.

## Conditions treated

- [Psoriasis](https://ourhealthnetwork.com/conditions/psoriasis)

## Mechanism of action

Risankizumab-rzaa is a humanized IgG1 monoclonal antibody that selectively binds to the p19 subunit of human IL-23 cytokine and inhibits its interaction with the IL-23 receptor. IL-23 is a naturally occurring cytokine that is involved in inflammatory and immune responses.

## Drug classification

- Established Pharmacologic Class: Interleukin-23 Antagonist [EPC]
- Mechanism of Action class: Interleukin-23 Antagonists [MoA]
- Route of administration: SUBCUTANEOUS

## Common side effects

fatigue, headache, injection site reactions, tinea infections

## Sources and disclaimers

- FDA Orange Book and OpenFDA dataset
- This information is for educational purposes only and does not constitute medical advice. Always consult a healthcare professional before starting, stopping, or changing any medication.

## Related

- [All drugs](https://ourhealthnetwork.com/drugs)
- [Find specialists who prescribe this drug](https://ourhealthnetwork.com/find-doctors)
- [Methodology](https://ourhealthnetwork.com/methodology)